Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K. Yamamoto N, et al. Among authors: hirase s. Eur J Pediatr. 2014 Dec;173(12):1615-8. doi: 10.1007/s00431-013-2181-6. Epub 2013 Oct 30. Eur J Pediatr. 2014. PMID: 24169729
Primary pediatric endobronchial Ewing sarcoma family of tumors.
Hayakawa A, Hirase S, Matsunoshita N, Yamamoto N, Kubokawa I, Mori T, Yanai T, Maniwa Y, Iijima K. Hayakawa A, et al. Among authors: hirase s. Am J Case Rep. 2013;14:67-9. doi: 10.12659/AJCR.883821. Epub 2013 Mar 5. Am J Case Rep. 2013. PMID: 23569566 Free PMC article.
Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H, Yamamoto T, Morikawa S, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Iijima K, Matsuo M, Nishio H, Nishimura N. Hartomo TB, et al. Among authors: hirase s. Oncol Rep. 2013 Apr;29(4):1629-36. doi: 10.3892/or.2013.2286. Epub 2013 Feb 12. Oncol Rep. 2013. PMID: 23417100
Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia.
Hirase S, Hasegawa D, Takahashi H, Moriwaki K, Saito A, Kozaki A, Ishida T, Yanai T, Kawasaki K, Yamamoto N, Kubokawa I, Mori T, Hayakawa A, Nishimura N, Nishio H, Iijima K, Kosaka Y. Hirase S, et al. Int J Hematol. 2015 Nov;102(5):594-601. doi: 10.1007/s12185-015-1875-0. Epub 2015 Oct 6. Int J Hematol. 2015. PMID: 26440971 Clinical Trial.
Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
Yamamoto N, Kozaki A, Hartomo TB, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Hirase S, Mori T, Hayakawa A, Iijima K, Nishio H, Nishimura N. Yamamoto N, et al. Among authors: hirase s. Oncol Lett. 2015 Nov;10(5):3228-3232. doi: 10.3892/ol.2015.3710. Epub 2015 Sep 16. Oncol Lett. 2015. PMID: 26722317 Free PMC article.
41 results